The avian flu treatment market size has grown strongly in recent years. It will grow from $13.77 billion in 2025 to $15.04 billion in 2026 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to increasing incidence of avian influenza outbreaks, reliance on antiviral stockpiling strategies, government-led disease control initiatives, expansion of hospital-based infectious disease treatment, increased public health awareness.
The avian flu treatment market size is expected to see strong growth in the next few years. It will grow to $20.6 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to increasing investments in zoonotic disease research, rising development of next-generation vaccines, expansion of global disease surveillance networks, growing focus on rapid response therapeutics, increased international collaboration on pandemic preparedness. Major trends in the forecast period include increasing adoption of advanced antiviral therapies, rising focus on rapid vaccine development platforms, growing use of monoclonal antibody treatments, expansion of early diagnosis and surveillance programs, enhanced focus on pandemic preparedness.
The increasing awareness and improved diagnosis are expected to propel the growth of the avian flu treatment market in the coming years. Awareness refers to the understanding of a condition, while diagnosis involves identifying a specific issue based on that understanding. The demand for avian flu treatment stems from the critical need to protect public health, prevent potential pandemics, and safeguard poultry populations from substantial economic losses. Awareness and early diagnosis are essential for effective avian flu treatment, allowing timely intervention and containment to prevent further spread. For example, in April 2024, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, over 8,000 individuals in the US were under active surveillance from February 9, 2022, to March 29, 2024, after being exposed to animals suspected of carrying the HPAI A (H5N1) virus. Consequently, increasing awareness and diagnosis are driving growth in the avian flu treatment market.
Major companies in the avian flu treatment market are concentrating on forming partnerships to improve efficacy and accelerate the development of new therapies. These partnerships involve collaborations among pharmaceutical companies, research institutions, and government agencies to combine resources, share expertise, and conduct innovative clinical trials. For example, in April 2024, CureVac N.V., a Germany-based biotechnology company, collaborated with GSK plc, a UK-based pharmaceutical company, to develop an investigational influenza A (H5N1) pre-pandemic vaccine candidate aimed at addressing the potential future pandemic threat from the H5N1 avian influenza virus. This collaboration is focused on evaluating the safety, reactogenicity, and immunogenicity of the monovalent vaccine candidate, which encodes an influenza A H5 antigen using CureVac's proprietary second-generation mRNA platform. The combined Phase 1/2 study will assess the vaccine candidate's safety and efficacy in healthy adults aged 18 to 64, as well as in older adults aged 65 to 85.
In November 2025, Merck & Co. (MSD), a U.S.-based biopharmaceutical company, announced its agreement to acquire Cidara Therapeutics, Inc. for $9.2 billion in cash. Through this acquisition, Merck intends to diversify and enhance its respiratory and antiviral portfolio by incorporating Cidara’s proprietary long-acting antiviral, CD388, which is designed for broad and durable influenza prevention. Cidara Therapeutics, a U.S.-based company, develops drug-Fc conjugate (DFC) therapeutics utilizing its Cloudbreak platform, and its lead candidate CD388 is a strain-agnostic investigational antiviral currently undergoing Phase III trials.
Major companies operating in the avian flu treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline Plc, Novartis AG, AstraZeneca Plc, Gilead Sciences Inc., CSL Limited, Moderna Inc., Shionogi & Co. Ltd., Cipla Ltd., Seqirus, Novavax Inc., Sinovac Biotech Ltd., Valneva SE, CureVac AG, BioCryst Pharmaceuticals Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Baxter International Inc., Takeda Pharmaceutical Company Limited.
North America was the largest region in the avian flu treatment market in 2025. Asia-Pacific is expected to be the fastest growing region in the market. The regions covered in the avian flu treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the avian flu treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the avian flu treatment market by increasing costs of imported active pharmaceutical ingredients, biologics manufacturing equipment, cold-chain logistics systems, and diagnostic reagents used in antiviral and vaccine production. Asia-Pacific and Europe are most affected due to cross-border pharmaceutical supply dependencies, while North America faces higher production input costs. These tariffs are contributing to increased treatment costs and slower stockpile replenishment. However, they are also encouraging domestic pharmaceutical manufacturing, localized vaccine production, and regional supply chain strengthening to improve outbreak response readiness.
The avian flu treatment market research report is one of a series of new reports that provides avian flu treatment market statistics, including avian flu treatment industry global market size, regional shares, competitors with a avian flu treatment market share, detailed avian flu treatment market segments, market trends and opportunities, and any further data you may need to thrive in the avian flu treatment industry. This avian flu treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Avian flu treatment involves medical interventions and strategies designed to manage and reduce the symptoms of avian influenza, commonly called bird flu, in affected individuals. Avian influenza is caused by viruses that mainly infect birds, but certain strains, including H5N1 and H7N9, can infect humans and may lead to severe illness or, in some cases, death.
The primary types of avian flu treatment include antibiotics, vaccines, antiviral agents, and immunoglobulins. Antibiotics are medications used to combat bacterial infections. The distribution channels consist of both online and offline pharmacies, serving various end-users such as hospitals, institutional health centers, and clinics.
The avian flu treatment market consists of sales of antiviral medications, respiratory support equipment, and intravenous fluids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The avian flu treatment market size is expected to see strong growth in the next few years. It will grow to $20.6 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to increasing investments in zoonotic disease research, rising development of next-generation vaccines, expansion of global disease surveillance networks, growing focus on rapid response therapeutics, increased international collaboration on pandemic preparedness. Major trends in the forecast period include increasing adoption of advanced antiviral therapies, rising focus on rapid vaccine development platforms, growing use of monoclonal antibody treatments, expansion of early diagnosis and surveillance programs, enhanced focus on pandemic preparedness.
The increasing awareness and improved diagnosis are expected to propel the growth of the avian flu treatment market in the coming years. Awareness refers to the understanding of a condition, while diagnosis involves identifying a specific issue based on that understanding. The demand for avian flu treatment stems from the critical need to protect public health, prevent potential pandemics, and safeguard poultry populations from substantial economic losses. Awareness and early diagnosis are essential for effective avian flu treatment, allowing timely intervention and containment to prevent further spread. For example, in April 2024, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, over 8,000 individuals in the US were under active surveillance from February 9, 2022, to March 29, 2024, after being exposed to animals suspected of carrying the HPAI A (H5N1) virus. Consequently, increasing awareness and diagnosis are driving growth in the avian flu treatment market.
Major companies in the avian flu treatment market are concentrating on forming partnerships to improve efficacy and accelerate the development of new therapies. These partnerships involve collaborations among pharmaceutical companies, research institutions, and government agencies to combine resources, share expertise, and conduct innovative clinical trials. For example, in April 2024, CureVac N.V., a Germany-based biotechnology company, collaborated with GSK plc, a UK-based pharmaceutical company, to develop an investigational influenza A (H5N1) pre-pandemic vaccine candidate aimed at addressing the potential future pandemic threat from the H5N1 avian influenza virus. This collaboration is focused on evaluating the safety, reactogenicity, and immunogenicity of the monovalent vaccine candidate, which encodes an influenza A H5 antigen using CureVac's proprietary second-generation mRNA platform. The combined Phase 1/2 study will assess the vaccine candidate's safety and efficacy in healthy adults aged 18 to 64, as well as in older adults aged 65 to 85.
In November 2025, Merck & Co. (MSD), a U.S.-based biopharmaceutical company, announced its agreement to acquire Cidara Therapeutics, Inc. for $9.2 billion in cash. Through this acquisition, Merck intends to diversify and enhance its respiratory and antiviral portfolio by incorporating Cidara’s proprietary long-acting antiviral, CD388, which is designed for broad and durable influenza prevention. Cidara Therapeutics, a U.S.-based company, develops drug-Fc conjugate (DFC) therapeutics utilizing its Cloudbreak platform, and its lead candidate CD388 is a strain-agnostic investigational antiviral currently undergoing Phase III trials.
Major companies operating in the avian flu treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline Plc, Novartis AG, AstraZeneca Plc, Gilead Sciences Inc., CSL Limited, Moderna Inc., Shionogi & Co. Ltd., Cipla Ltd., Seqirus, Novavax Inc., Sinovac Biotech Ltd., Valneva SE, CureVac AG, BioCryst Pharmaceuticals Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Baxter International Inc., Takeda Pharmaceutical Company Limited.
North America was the largest region in the avian flu treatment market in 2025. Asia-Pacific is expected to be the fastest growing region in the market. The regions covered in the avian flu treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the avian flu treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the avian flu treatment market by increasing costs of imported active pharmaceutical ingredients, biologics manufacturing equipment, cold-chain logistics systems, and diagnostic reagents used in antiviral and vaccine production. Asia-Pacific and Europe are most affected due to cross-border pharmaceutical supply dependencies, while North America faces higher production input costs. These tariffs are contributing to increased treatment costs and slower stockpile replenishment. However, they are also encouraging domestic pharmaceutical manufacturing, localized vaccine production, and regional supply chain strengthening to improve outbreak response readiness.
The avian flu treatment market research report is one of a series of new reports that provides avian flu treatment market statistics, including avian flu treatment industry global market size, regional shares, competitors with a avian flu treatment market share, detailed avian flu treatment market segments, market trends and opportunities, and any further data you may need to thrive in the avian flu treatment industry. This avian flu treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Avian flu treatment involves medical interventions and strategies designed to manage and reduce the symptoms of avian influenza, commonly called bird flu, in affected individuals. Avian influenza is caused by viruses that mainly infect birds, but certain strains, including H5N1 and H7N9, can infect humans and may lead to severe illness or, in some cases, death.
The primary types of avian flu treatment include antibiotics, vaccines, antiviral agents, and immunoglobulins. Antibiotics are medications used to combat bacterial infections. The distribution channels consist of both online and offline pharmacies, serving various end-users such as hospitals, institutional health centers, and clinics.
The avian flu treatment market consists of sales of antiviral medications, respiratory support equipment, and intravenous fluids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Avian Flu Treatment Market Characteristics
3. Avian Flu Treatment Market Supply Chain Analysis
4. Global Avian Flu Treatment Market Trends and Strategies
5. Avian Flu Treatment Market Analysis of End Use Industries
7. Global Avian Flu Treatment Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Avian Flu Treatment Total Addressable Market (TAM) Analysis for the Market
9. Avian Flu Treatment Market Segmentation
10. Avian Flu Treatment Market Regional and Country Analysis
11. Asia-Pacific Avian Flu Treatment Market
12. China Avian Flu Treatment Market
13. India Avian Flu Treatment Market
14. Japan Avian Flu Treatment Market
15. Australia Avian Flu Treatment Market
16. Indonesia Avian Flu Treatment Market
17. South Korea Avian Flu Treatment Market
18. Taiwan Avian Flu Treatment Market
19. South East Asia Avian Flu Treatment Market
20. Western Europe Avian Flu Treatment Market
21. UK Avian Flu Treatment Market
22. Germany Avian Flu Treatment Market
23. France Avian Flu Treatment Market
24. Italy Avian Flu Treatment Market
25. Spain Avian Flu Treatment Market
26. Eastern Europe Avian Flu Treatment Market
27. Russia Avian Flu Treatment Market
28. North America Avian Flu Treatment Market
29. USA Avian Flu Treatment Market
30. Canada Avian Flu Treatment Market
31. South America Avian Flu Treatment Market
32. Brazil Avian Flu Treatment Market
33. Middle East Avian Flu Treatment Market
34. Africa Avian Flu Treatment Market
36. Avian Flu Treatment Market Competitive Landscape and Company Profiles
37. Avian Flu Treatment Market Other Major and Innovative Companies
40. Avian Flu Treatment Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Avian Flu Treatment Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses avian flu treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for avian flu treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The avian flu treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Vaccines; Antiviral Agents; Immunoglobulins2) By Distribution Channel: Online Pharmacies; Offline Pharmacies
3) By End User: Hospital; Institutional Health Centers; Clinics
Subsegments:
1) By Vaccines: Inactivated Vaccines; Live Attenuated Vaccines; Recombinant Vaccines; Subunit Vaccines; Dna Vaccines; Bivalent And Multivalent Vaccines2) By Antiviral Agents: Neuraminidase Inhibitors (Oseltamivir, Zanamivir); Polymerase Inhibitors; Antiviral Combination Therapies
3) By Immunoglobulins: Human Immunoglobulin (Ivig); Monoclonal Antibodies; Hyperimmune Serum; Polyvalent Immunoglobulins; Avian Flu-Specific Immunoglobulins
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Sanofi S.A.; GlaxoSmithKline Plc; Novartis AG; AstraZeneca Plc; Gilead Sciences Inc.; CSL Limited; Moderna Inc.; Shionogi & Co. Ltd.; Cipla Ltd.; Seqirus; Novavax Inc.; Sinovac Biotech Ltd.; Valneva SE; CureVac AG; BioCryst Pharmaceuticals Inc.; Emergent BioSolutions Inc.; Dynavax Technologies Corporation; Baxter International Inc.; Takeda Pharmaceutical Company Limited
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Avian Flu Treatment market report include:- Pfizer Inc.
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Sanofi S.A.
- GlaxoSmithKline Plc
- Novartis AG
- AstraZeneca Plc
- Gilead Sciences Inc.
- CSL Limited
- Moderna Inc.
- Shionogi & Co. Ltd.
- Cipla Ltd.
- Seqirus
- Novavax Inc.
- Sinovac Biotech Ltd.
- Valneva SE
- CureVac AG
- BioCryst Pharmaceuticals Inc.
- Emergent BioSolutions Inc.
- Dynavax Technologies Corporation
- Baxter International Inc.
- Takeda Pharmaceutical Company Limited
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 15.04 Billion |
| Forecasted Market Value ( USD | $ 20.6 Billion |
| Compound Annual Growth Rate | 8.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 23 |
